Plant breeders at the University of Wisconsin-Madison have developed an oat variety that features more beta glucans than common oats.
Plant breeders at the University of Wisconsin-Madison have developed BetaGene, a high-yield oat variety that features more beta glucans than the oats commonly available in today’s market.
Beta glucans have become a focal point for research, among other conditions, on heart health. Consumption of these compounds has been linked to cholesterol reductions, and FDA, EFSA, and Health Canada all have cardiovascular health claims for either oat fiber or oat beta glucans.
BetaGene is an estimated 2% higher in beta glucans than common varieties. While the increase sounds small, the University explains that it translates to a 20% boost in beta glucans in products ready to market.
The food industry has already taken interest in BetaGene, with at least one large milling company reported to have visited the area to learn more about the oat.
BetaGene is the result of a cross-breed developed in 1998.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.